As of June 30, 17 new stem cell drugs in China have been approved to enter clinical trials with tacit consent in 2024 (implicit approval for clinical trials), and 4 are being accepted.

17 clinical implied licenses

Mesenchymal stem cells: 14 models

Hematopoietic stem cells: 3 types

4 items are being accepted